Connor, Clark & Lunn Investment Management (CC&L)’s Emergent Biosolutions EBS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.29M | Buy |
986,673
+55,046
| +6% | +$351K | 0.02% | 516 |
|
|
2025
Q1 | $4.53M | Buy |
931,627
+29,295
| +3% | +$142K | 0.02% | 525 |
|
|
2024
Q4 | $8.63M | Buy |
902,332
+69,157
| +8% | +$661K | 0.04% | 360 |
|
|
2024
Q3 | $6.96M | Sell |
833,175
-10,213
| -1% | -$85.3K | 0.03% | 364 |
|
|
2024
Q2 | $5.75M | Buy |
843,388
+137,153
| +19% | +$935K | 0.02% | 397 |
|
|
2024
Q1 | $1.79M | Buy |
706,235
+495,781
| +236% | +$1.25M | 0.01% | 704 |
|
|
2023
Q4 | $505K | Buy |
210,454
+920
| +0.4% | +$2.21K | ﹤0.01% | 1045 |
|
|
2023
Q3 | $712K | Buy |
+209,534
| New | +$712K | ﹤0.01% | 929 |
|
|
2023
Q2 | – | Sell |
-45,855
| Closed | -$475K | – | 1366 |
|
|
2023
Q1 | $475K | Buy |
+45,855
| New | +$475K | ﹤0.01% | 898 |
|
|
2020
Q4 | – | Sell |
-39,350
| Closed | -$4.07M | – | 934 |
|
|
2020
Q3 | $4.07M | Buy |
39,350
+16,929
| +76% | +$1.75M | 0.03% | 344 |
|
|
2020
Q2 | $1.77M | Buy |
+22,421
| New | +$1.77M | 0.01% | 481 |
|
|
2016
Q1 | – | Sell |
-50,400
| Closed | -$2.02M | – | 849 |
|
|
2015
Q4 | $2.02M | Buy |
50,400
+9,900
| +24% | +$396K | 0.02% | 338 |
|
|
2015
Q3 | $1.15M | Buy |
40,500
+34,400
| +564% | +$980K | 0.01% | 377 |
|
|
2015
Q2 | $201K | Buy |
+6,100
| New | +$201K | ﹤0.01% | 562 |
|
|
2014
Q2 | – | Sell |
-54,011
| Closed | -$1.51M | – | 556 |
|
|
2014
Q1 | $1.51M | Buy |
54,011
+23,900
| +79% | +$666K | 0.01% | 314 |
|
|
2013
Q4 | $736K | Sell |
30,111
-700
| -2% | -$17.1K | 0.01% | 427 |
|
|
2013
Q3 | $603K | Buy |
30,811
+5,711
| +23% | +$112K | 0.01% | 329 |
|
|
2013
Q2 | $382K | Buy |
+25,100
| New | +$382K | ﹤0.01% | 392 |
|